Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 May 2018 Status changed from not yet recruiting to recruiting.
- 29 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
- 27 Feb 2018 New trial record